Neuromodulation
SACRAL NEUROMODULATION
Appears to have a high reintervention rate as shown in the cohort of 4946 New York patients between 2008 and 2015, 20% of whom were male. Most had the procedure due to wet overactive bladder (n = 2534 [51.2%]). Reinterventions rates were 13.7% within 1 year, 26.3% within 3 years, and 38.0% within 5 years following SNM placement. Most commonly was due to treatment failure (47.0%) and device malfunction (47.3%) at 1 year. At 5 years, 33.0% were due to treatment failure and 63.8% to device malfunctions . There were no significant differences between high vs low volume hospitals or surgeons. (1)
COMPARED TO BOTOX
Showed botox had small improvement in number of episodes with increased risk for UTI and self catheterization. (2)
Appears to have a high reintervention rate as shown in the cohort of 4946 New York patients between 2008 and 2015, 20% of whom were male. Most had the procedure due to wet overactive bladder (n = 2534 [51.2%]). Reinterventions rates were 13.7% within 1 year, 26.3% within 3 years, and 38.0% within 5 years following SNM placement. Most commonly was due to treatment failure (47.0%) and device malfunction (47.3%) at 1 year. At 5 years, 33.0% were due to treatment failure and 63.8% to device malfunctions . There were no significant differences between high vs low volume hospitals or surgeons. (1)
COMPARED TO BOTOX
Showed botox had small improvement in number of episodes with increased risk for UTI and self catheterization. (2)
- Chughtai, Bilal, et al. "Failures of Sacral Neuromodulation for Incontinence." JAMA surgery (2018).
- Amundsen, Cindy L., et al. “OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.” JAMA, vol. 316, no. 13, 2016, pp. 1366–1374.